Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Open Forum Infect Dis ; 11(3): ofae016, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38434609

ABSTRACT

The Infectious Diseases Society of America Training Program Directors Committee met in October 2022 and discussed an observed increase in clinical volume and acuity on infectious diseases (ID) services, and its impact on fellow education. Committee members sought to develop specific goals and strategies related to improving training program culture, preserving quality education on inpatient consult services and in the clinic, and negotiating change at the annual IDWeek Training Program Director meeting. This paper outlines a presentation of ideas brought forth at the meeting and is meant to serve as a reference document for infectious diseases training program directors seeking guidance in this area.

2.
AIDS Behav ; 28(3): 912-923, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37872460

ABSTRACT

The purpose of this study is to describe telehealth experiences and quality of HIV care provided to an urban population of people with HIV (PWH) in Washington, DC. We used self-reported survey data from a cohort of PWH in the DC Cohort longitudinal study linked to medical records (October 26, 2020-December 31, 2021). Analyses followed a mixed-methods approach, including prevalence estimates and multivariable logistic regression of telehealth use by demographic and HIV characteristics. We measured primary motivation, modes of engagement, and telehealth satisfaction. Qualitative responses to open-ended questions were coded using collaborative coding. A framework developed by the National Quality Forum (NQF) was applied to the results. Among 978 participants, 69% reported using telehealth for HIV care during the pandemic. High school graduates were less likely to use telehealth compared to those with college education (aOR 0.69, 95% CI 0.48, 0.98). PWH with > 1 co-morbid condition were more likely to use telehealth compared to those without (aOR 1.42, 95% CI 1.02, 1.95). The majority reported satisfaction with telehealth (81%). Qualitative analysis of telehealth satisfaction found that most responses were related to access to care and technology, effectiveness, and patient experience. PWH using telehealth during the pandemic were satisfied with their experience though use differed demographically. Telehealth was used effectively to overcome barriers to care engagement, including transportation, costs, and time. As we transition away from the emergency pandemic responses, it will be important to determine how this technology can be used in the future in an equitable manner to further strengthen HIV care engagement.


Subject(s)
COVID-19 , HIV Infections , Telemedicine , Humans , COVID-19/epidemiology , District of Columbia/epidemiology , Longitudinal Studies , Pandemics , HIV Infections/epidemiology , HIV Infections/therapy
3.
Open Forum Infect Dis ; 10(6): ofad289, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37397270

ABSTRACT

The Infectious Diseases Society of America (IDSA) has set clear priorities in recent years to promote inclusion, diversity, access, and equity (IDA&E) in infectious disease (ID) clinical practice, medical education, and research. The IDSA IDA&E Task Force was launched in 2018 to ensure implementation of these principles. The IDSA Training Program Directors Committee met in 2021 and discussed IDA&E best practices as they pertain to the education of ID fellows. Committee members sought to develop specific goals and strategies related to recruitment, clinical training, didactics, and faculty development. This article represents a presentation of ideas brought forth at the meeting in those spheres and is meant to serve as a reference document for ID training program directors seeking guidance in this area.

4.
Open Forum Infect Dis ; 8(2): ofaa583, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33553468

ABSTRACT

One of the many challenges that has befallen the Infectious Diseases and Graduate Medical Education communities during the coronavirus disease 2019 (COVID-19) pandemic is the maintenance of continued effective education and training of the future leaders of our field. With the remarkable speed and innovation that has characterized the responses to this pandemic, educators everywhere have adapted existing robust and safe learning environments to meet the needs of our learners. This paper will review distinct aspects of education and training of the Infectious Diseases fellows we believe the COVID-19 pandemic has impacted most, including mentoring, didactics, and wellness. We anticipate that several strategies developed in this context and described herein will help to inform training and best practices during the pandemic and beyond.

5.
Open Forum Infect Dis ; 8(2): ofab021, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33623804

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has affected many providers, but its impact on Infectious Diseases (ID) fellows in the United States is largely undescribed. In this study, we discuss key issues that emerged from the first national ID Fellows Call with respect to the ID fellow's role during the COVID-19 pandemic, teaching/learning, and research.

6.
Pharmacotherapy ; 37(8): e82-e89, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28556353

ABSTRACT

The use of enteral feeding tubes to administer antiretroviral medications is necessary in certain patients with human immunodeficiency virus (HIV) infection. However, adequacy of drug exposures after these administration routes are largely unknown, making dosing recommendations and the attainment of viral suppression challenging in this patient population. This report describes a patient with advanced HIV infection and a complicated medical history including long-term intractable nausea/vomiting necessitating antiretroviral medication administration via a Roux-en-Y jejunostomy (J)-tube. Pharmacokinetic assessments were performed to compare differences in antiretroviral drug absorption and plasma exposure following oral and J-tube administration of dolutegravir, tenofovir disoproxil fumarate, and emtricitabine. Results were also compared with published pharmacokinetic data in HIV-infected individuals. Exposure to dolutegravir and tenofovir were similar between J-tube and oral administration routes, whereas emtricitabine exposure was 38% lower when administered via J-tube. However, in comparison with reference data in HIV-infected individuals taking these medications orally, exposure to dolutegravir and tenofovir was 75-76% and 55-61% lower, respectively, following both routes of administration. Emtricitabine exposure was similar to and 71% higher than reference data following J-tube and oral administration, respectively. This report highlights the importance of performing pharmacokinetic assessments in patients with the potential for impaired drug absorption to ensure antiretroviral treatment success.


Subject(s)
Anti-HIV Agents/pharmacokinetics , HIV Infections , Administration, Oral , Anti-HIV Agents/blood , Drug Therapy, Combination , Emtricitabine/blood , Emtricitabine/pharmacokinetics , Enteral Nutrition , Heterocyclic Compounds, 3-Ring/blood , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Humans , Jejunostomy , Male , Middle Aged , Oxazines , Piperazines , Pyridones , Tenofovir/blood , Tenofovir/pharmacokinetics
7.
Infect Dis Clin North Am ; 27(2): 271-83, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23714340

ABSTRACT

Renal transplant recipients continue to have progressive kidney dysfunction and renal graft loss has been attributed to emerging opportunistic infections, specifically BK virus (BKV). BKV is postulated to be selected by the new potent immunosuppressive medications and to be an important factor in graft failure. The prevalence of BKV nephropathy (BKVN) is estimated to be 1% to 10% and renal allograft loss from BKVN has been estimated to occur in up to 50% of affected recipients. With the increasing recognition of BKV infection using PCR assays coupled with the immediate reduction in immunosuppression for BKVN, the incidence of graft failure secondary to BKVN may be decreasing.


Subject(s)
BK Virus/isolation & purification , Immunocompromised Host , Kidney Transplantation , Polyomavirus Infections/diagnosis , Polyomavirus Infections/drug therapy , Transplantation , Antiviral Agents/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Incidence , Plasma/virology , Polyomavirus Infections/epidemiology , Polyomavirus Infections/virology , Treatment Failure , Urine/virology
9.
Am J Med ; 119(5): 448.e21-5, 2006 May.
Article in English | MEDLINE | ID: mdl-16651059

ABSTRACT

BACKGROUND: From October 2001 to October 2002, we have observed a surprisingly high incidence of ocular syphilis in human immunodeficiency virus-positive (HIV+) patients receiving highly active antiretroviral therapy at our clinic. METHODS: We conducted a retrospective chart and patient database review. RESULTS: From 1997 to 2002, 455 patients in our clinic were screened for syphilis; 320 were screened from 2001 to 2002; 7.3% of patients (33/455) were diagnosed with syphilis. During the past year, syphilis was diagnosed in 7.5% of patients (24/320), of whom 13% (3/24) had ocular syphilis. We estimate the prevalence of ocular syphilis in HIV+ patients on highly active antiretroviral therapy screened for syphilis to be 9% (3/33). Presenting symptoms included blurred vision, loss of vision, central scotomas, and bilateral ocular involvement. The most common ocular manifestation of syphilis was posterior chamber uveitis; one patient also had a retinal detachment. All patients demonstrated reactive rapid plasma reagin and fluorescent treponemal antibody absorption test results, cerebrospinal fluid pleocytosis, and elevated total protein. Each patient received a 21-day course of intravenous penicillin G (24 million units daily) with improvement of visual symptoms. CONCLUSION: Our data demonstrate an unexpectedly high incidence of ocular syphilis in our HIV+ patients receiving highly active antiretroviral therapy during the past year. A diagnosis of ocular syphilis should be considered in any HIV+ patient who presents with visual symptoms, irrespective of the patient's CD4 count.


Subject(s)
Antiretroviral Therapy, Highly Active , Eye Diseases/microbiology , Eye Diseases/virology , HIV Infections/complications , HIV Infections/drug therapy , Syphilis/virology , Eye Diseases/epidemiology , Eye Diseases/etiology , Humans , Incidence , Retrospective Studies , Syphilis/epidemiology , Syphilis/etiology , Uveitis/etiology , Uveitis/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...